QURE stock news today

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Analysts adjust their views on uniQure N.V.

Wall Street analysts changed their recommendations and target prices for uniQure N.V. No specific figures or direction were given.

uniQure Posts Q3 2026 Results

The biopharma company shared its numbers for the July-to-September period of 2026. The release covers how the business performed in that quarter.

uniQure holds Q3 2026 earnings call

uniQure discussed its third-quarter 2026 results on an earnings call. The headline gives no figures or details beyond the call itself.

uniQure posts smaller quarterly loss than expected, revenue falls short

The biotech company's third-quarter loss per share was narrower than analysts had projected. Its revenue for the period came in below the consensus estimate.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

FDA advances uniQure's Huntington therapy; analyst downplays softening signals

The FDA is moving uniQure's Huntington disease therapy forward in the review process. An analyst said softening signals around the program are not a concern.

uniQure says FDA accepts and grants priority review to its Huntington's disease gene therapy BLA

uniQure announced that the FDA has accepted its Biologics License Application for a Huntington's disease gene therapy and granted it priority review. Priority review shortens the agency's review timeline for the application.

uniQure rating cut to Equal-Weight by Barclays, target now $28

Barclays moved its stance on uniQure to Equal-Weight and trimmed its price target to $28. The adjustment reflects the firm's updated view of the shares.

RBC Capital keeps Outperform rating on uniQure, cuts price target to $48

RBC Capital reiterated its Outperform rating on uniQure while reducing its price target to $48. The update reflects the analyst's revised expectations for the stock.

Goldman Sachs keeps Neutral rating on uniQure, cuts target to $31

Goldman Sachs left its Neutral rating on uniQure unchanged while reducing its price target to $31. The adjustment reflects the firm's updated view on the stock.

Crude Oil Falls 1% as US Job Openings Decline in August

Crude oil prices dropped 1% while US job openings decreased in August. The data points to a cooling labor market alongside weaker oil prices.

uniQure reports 44% slowing in disease progression measure, not statistically significant

uniQure said its cUHDRS measure indicated a 44% reduction in disease progression versus a revised external control. The finding fell short of statistical significance, and the stock moved lower.

uniQure posts 48-month Phase I/II results for Huntington's therapy ifezuntirgene inilparvovec

uniQure shared new findings from ongoing Phase I/II trials of ifezuntirgene inilparvovec in Huntington's disease. At 48 months, the dozen participants on the higher dose kept showing slower progression on cUHDRS and TFC, with a dose-dependent pattern and 44% slowing on the primary cUHDRS measure.

William Blair Reinstates Outperform Rating on uniQure

William Blair has reinstated its Outperform rating on uniQure. The rating indicates the firm's positive view on the company's stock.

uniQure Files for Huntington's Disease Approval

uniQure has submitted an application seeking approval for a Huntington's disease treatment. An analyst said the application's acceptance is the key upcoming catalyst.

uniQure seeks FDA accelerated approval for ifezuntirgene inilparvovec

uniQure has filed paperwork with the FDA asking for faster clearance of its therapy ifezuntirgene inilparvovec. A separate marketing submission for the same treatment went to the MHRA.

uniQure seeks FDA accelerated approval for AMT-130 in Huntington's

uniQure has filed a Biologics License Application with the FDA for accelerated approval of AMT-130, a treatment aimed at Huntington's disease. The submission begins the agency's review of the therapy.

What is the latest news on QURE?

Nov 10, 2026: uniQure N.V. filed an insider trading report (Form 4) (SEC) · Nov 7, 2026: Analysts adjust their views on uniQure N.V. (Fiscal.ai) · Nov 4, 2026: uniQure Posts Q3 2026 Results (Fiscal.ai)

What has QURE filed with the SEC recently?

Nov 10, 2026: uniQure N.V. filed an insider trading report (Form 4) · Nov 4, 2026: uniQure N.V. filed a report on a major company event (Form 8-K)